This marks a significant new indication for cadonilimab beyond gastric, lung, and cervical cancers, and represents the 13th Phase III/registrational study of the therapy conducted globally.

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for ...

The FDA has approved atezolizumab with chemotherapy after surgery for stage III colon cancer with deficient mismatch repair, ...

I was hospitalized for the first time in my life for colon cancer surgery—it was okay to say, 'I'm scared'In my previous ...

Colorectal cancer most often spreads to the liver. When those liver tumors (called liver metastases) can be removed with ...

Genentech, part of Roche Group (USOTC:RHHBY), has received FDA approval for Tecentriq in combination with chemotherapy for a ...

“Does colorectal cancer surgery mean the anus can’t be preserved?” ... A specialist answers ...

The Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) in combination with chemotherapy on Oct. 8 as an ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq ® (atezolizumab) and Tecentriq Hybreza ® ...

FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, ...

Exercise helped colon cancer survivors live longer in a major trial. But an October 6 report in The New York Times highlights ...

Tecentriq is now the first immunotherapy indicated for dMMR colon cancer treatment specifically, which is often linked to a higher risk of progression after surgery.